ArticleFrontiers in immunology2024
Design of a novel EmTSP-3 and EmTIP based multi-epitope vaccine against
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Alveolar Echinococcosis in the Early 2020s: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- The hydatid cyst fluid protein EgAgB8/1 demonstrates potent immunogenicity by eliciting robust humoral and cellular immune responses in mice.PLoS neglected tropical diseases · 2026Article
- Intracellular Parasitic Infections Caused byVaccines · 2025Review
- Reverse vaccinology-driven construction and bioinformatics validation of a multi-epitope vaccine against Brucella spp.Scientific reports · 2025Article
- A novel multi-epitope mRNA vaccine against colorectal cancer: in silico design and immune efficacy profiling.Frontiers in immunology · 2025Article
- Development and protective efficacy of multi-epitope vaccine FL46 against cystic echinococcosis.Frontiers in immunology · 2025Article
- Computational epitope profiling and AI-driven protein engineering enable rational design of multi-epitope vaccines againstComputational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current treatments and prevention strategies for echinococcosis are inadequate. Recent advancements in molecular vaccine development show promise against Methods: This study aimed to develop a MEV against alveolar echinococcosis. Key epitopes from the Results: The effective antigenicity and immunogenicity of MEV were demonstrated through immunoinformatics, as well as Conclusion: A total of 7 CTL, 7 HTL, 5 linear B-cell, and 2 conformational B-cell epitopes were identified. The vaccine has demonstrated effective antigenicity and immunogenicity against AE through molecular docking, immune simulation, molecular dynamics studies, and both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.